EPO and myelofibrosis: The patient was considered immunocompromised due to underlying myelofibrosis with disease-related cytopenias, particularly anemia and relative lymphopenia, which are recognized risk factors for opportunistic infection; erythropoietin therapy itself is not immunosuppressive.